Waldencast Faces Securities Fraud Investigation, Shares Drop 6.49%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 01 2026
0mins
Should l Buy WALD?
Source: PRnewswire
- Investigation Launched: Pomerantz LLP is investigating whether Waldencast plc has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- Financial Outlook Downgraded: In its Q2 2025 financial report, Waldencast projected net revenue for the full year to be broadly in line with 2024, with adjusted EBITDA margins only in the high single digits, significantly lower than the previously expected mid-teens growth, indicating a notable decline in profitability.
- Substantial Losses: The company reported a net loss of $185.2 million for the first half of 2025, primarily due to impairment charges of $132.1 million and $20 million on its Obagi Medical and Milk Makeup brands, reflecting a severe decline in brand value.
- Stock Price Reaction: Following the earnings report, Waldencast's Class A ordinary shares fell by $0.20, or 6.49%, closing at $2.88, indicating increasing market concerns regarding the company's future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WALD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WALD
Wall Street analysts forecast WALD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WALD is 3.75 USD with a low forecast of 3.50 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.800
Low
3.50
Averages
3.75
High
4.00
Current: 1.800
Low
3.50
Averages
3.75
High
4.00
About WALD
Waldencast plc is a global multi-brand beauty and wellness platform. It is focused on developing, acquiring, accelerating, and scaling conscious and purpose-driven brands. Its segments include Obagi Medical and Milk Makeup. The Obagi Medical segment sells advanced skincare products backed by science and formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and to protect and enhance skin tone and texture. Its portfolio of medical-grade skincare with consumer-centric, in-office injectable procedures includes Saypha ChIQ, and MagIQ lines of injectable hyaluronic acid gels. The Milk Makeup segment consists of the business of Milk. Its Milk’s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Its Milk Makeup segment offers over 250 products through its United States Website www.MilkMakeup.com and retail partners include Sephora globally and Ulta Beauty in the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Obagi Partners with DermFx for ALOHA Program Launch
- Strategic Partnership: Obagi Medical has formed a strategic alliance with DermFx to leverage the ALOHA program, translating FDA clinical trial safety and efficacy into practical applications, thereby enhancing DermFx's competitive edge in Southern California.
- Data-Driven Practice: The program will utilize standardized data capture and structured evaluations across multiple locations to help DermFx deliver superior patient experiences, ultimately increasing patient satisfaction and loyalty.
- Innovative Technology Application: The Obagi®saypha®MagIQ™ utilizes advanced MACRO Core technology to ensure natural-looking results and high hyaluronic acid content post-injection, enhancing treatment outcomes and market appeal for DermFx.
- Industry Leadership: This collaboration not only demonstrates Obagi's support for diverse medical practices but also underscores its leadership position in the rapidly growing professional skincare market, expected to drive future business growth.
See More
Obagi Partners with Moxie to Launch ALOHA Program
- Strategic Partnership: Obagi Medical has partnered with Moxie to launch the ALOHA Program, aimed at leveraging Moxie's all-in-one software and marketing solutions to help med spa entrepreneurs achieve predictable growth and profitability while enhancing clinical and operational excellence.
- Data-Driven Evaluation: Moxie will conduct a structured assessment of Obagi® saypha® MagIQ™ across its network of supported aesthetic practices, utilizing data-driven insights and expert coaching to generate substantial evidence on the filler’s integration into scalable aesthetic workflows.
- Enhanced Patient Experience: The ALOHA Program evaluates both clinical performance and patient experience, equipping providers with integrated Obagi protocols to drive satisfaction and loyalty, ensuring consistent treatment outcomes and strengthening market competitiveness.
- Innovative Technology Application: Obagi® saypha® MagIQ™ utilizes proprietary MACRO Core Technology to deliver natural-looking results and category-leading performance, ensuring high usable HA content upon injection and consistent gel distribution, further solidifying Obagi's leadership in the rapidly evolving aesthetic market.
See More
Obagi Launches New Lip Care Innovations
- Product Innovation: Obagi has launched two new lip care products, the Lip Therapy AHA + PHA Smoothing Micro-Peel and the SPF 30 Soothe & Protect Lip Treatment, designed to enhance lip health through scientifically-backed formulations that improve user experience.
- Clinical Validation: The new products have been dermatologist-tested, with users reporting significant improvements in the appearance and feel of their lips, indicating effectiveness in enhancing hydration and reducing fine lines.
- Market Positioning: Priced at $55 for the Micro-Peel and $40 for the Lip Treatment, these products are expected to be sold through professional channels and will be available on Obagi.com starting February 3, further solidifying Obagi's leadership in the professional skincare market.
- Brand Strategy: This product launch reflects Obagi's long-standing commitment to skincare innovation, aiming to provide professional-grade care that helps consumers achieve healthy, beautiful skin, thereby enhancing the brand's competitiveness in the rapidly growing skincare market.
See More
Obagi Partners with VIO Med Spa to Launch ALOHA Program
- Partnership Announcement: Obagi Medical has partnered with VIO Med Spa to launch the ALOHA Program, which aims to conduct a multi-site evaluation of the Obagi® saypha® MagIQ™ filler, leveraging VIO's innovative injectables and personalized wellness protocols to enhance patient outcomes and experiences.
- Clinical Assessment Focus: The program will standardize data collection to evaluate clinical performance and patient experience, ensuring robust real-world evidence in high-volume aesthetic settings, thereby elevating industry standards and practices.
- Training Initiative: The ALOHA Program will kick off at the upcoming VIO University training, providing two days of expert-led training for the VIO network, aimed at enhancing clinical excellence and patient satisfaction in aesthetic medicine.
- Technological Edge: The Obagi® saypha® MagIQ™, developed using Croma-Pharma GmbH's MACRO Core Technology, delivers high usable HA content and consistent gel distribution, ensuring natural-looking results and predictable injection outcomes, further solidifying Obagi's leadership in the professional skincare market.
See More
Waldencast Faces Securities Fraud Claims, Shares Drop 6.49%
- Investigation Launched: Pomerantz LLP is investigating whether Waldencast plc has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock price volatility.
- Financial Outlook Downgraded: In its Q2 2025 financial report, Waldencast projected net revenue for the full year to be broadly in line with 2024, with an adjusted EBITDA margin in the high single digits, significantly lower than the previously expected mid-teens growth, indicating a notable decline in profitability.
- Substantial Losses: The company reported a net loss of $185.2 million for the first half of 2025, primarily due to impairment charges of $132.1 million and $20 million on its Obagi Medical and Milk Makeup brands, reflecting severe brand value erosion.
- Stock Price Reaction: Following the earnings report, Waldencast's Class A ordinary shares fell by $0.20, or 6.49%, closing at $2.88, indicating a pessimistic market sentiment regarding the company's future prospects.
See More
Waldencast Faces Securities Fraud Claims, Shares Drop 6.49%
- Investigation Launched: Pomerantz LLP is investigating whether Waldencast plc has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock price volatility.
- Financial Outlook Downgraded: In its Q2 2025 earnings report, Waldencast projected full-year net revenue to be in line with 2024, with adjusted EBITDA margins in the high single digits, significantly lower than previous mid-teens guidance, indicating a notable decline in profitability.
- Substantial Loss Reported: The company reported a net loss of $185.2 million for the first half of 2025, primarily due to impairment charges of $132.1 million and $20 million on its Obagi Medical and Milk Makeup brands, highlighting significant challenges to brand value that may affect future investment appeal.
- Stock Price Reaction: Following the earnings report, Waldencast's Class A ordinary shares fell by $0.20, or 6.49%, closing at $2.88, reflecting the market's pessimistic sentiment regarding the company's outlook.
See More
Obagi Partners with DermFx for ALOHA Program Launch
- Strategic Partnership: Obagi Medical has formed a strategic alliance with DermFx to leverage the ALOHA program, translating FDA clinical trial safety and efficacy into practical applications, thereby enhancing DermFx's competitive edge in Southern California.
- Data-Driven Practice: The program will utilize standardized data capture and structured evaluations across multiple locations to help DermFx deliver superior patient experiences, ultimately increasing patient satisfaction and loyalty.
- Innovative Technology Application: The Obagi®saypha®MagIQ™ utilizes advanced MACRO Core technology to ensure natural-looking results and high hyaluronic acid content post-injection, enhancing treatment outcomes and market appeal for DermFx.
- Industry Leadership: This collaboration not only demonstrates Obagi's support for diverse medical practices but also underscores its leadership position in the rapidly growing professional skincare market, expected to drive future business growth.
See More
Obagi Partners with Moxie to Launch ALOHA Program
- Strategic Partnership: Obagi Medical has partnered with Moxie to launch the ALOHA Program, aimed at leveraging Moxie's all-in-one software and marketing solutions to help med spa entrepreneurs achieve predictable growth and profitability while enhancing clinical and operational excellence.
- Data-Driven Evaluation: Moxie will conduct a structured assessment of Obagi® saypha® MagIQ™ across its network of supported aesthetic practices, utilizing data-driven insights and expert coaching to generate substantial evidence on the filler’s integration into scalable aesthetic workflows.
- Enhanced Patient Experience: The ALOHA Program evaluates both clinical performance and patient experience, equipping providers with integrated Obagi protocols to drive satisfaction and loyalty, ensuring consistent treatment outcomes and strengthening market competitiveness.
- Innovative Technology Application: Obagi® saypha® MagIQ™ utilizes proprietary MACRO Core Technology to deliver natural-looking results and category-leading performance, ensuring high usable HA content upon injection and consistent gel distribution, further solidifying Obagi's leadership in the rapidly evolving aesthetic market.
See More
Obagi Launches New Lip Care Innovations
- Product Innovation: Obagi has launched two new lip care products, the Lip Therapy AHA + PHA Smoothing Micro-Peel and the SPF 30 Soothe & Protect Lip Treatment, designed to enhance lip health through scientifically-backed formulations that improve user experience.
- Clinical Validation: The new products have been dermatologist-tested, with users reporting significant improvements in the appearance and feel of their lips, indicating effectiveness in enhancing hydration and reducing fine lines.
- Market Positioning: Priced at $55 for the Micro-Peel and $40 for the Lip Treatment, these products are expected to be sold through professional channels and will be available on Obagi.com starting February 3, further solidifying Obagi's leadership in the professional skincare market.
- Brand Strategy: This product launch reflects Obagi's long-standing commitment to skincare innovation, aiming to provide professional-grade care that helps consumers achieve healthy, beautiful skin, thereby enhancing the brand's competitiveness in the rapidly growing skincare market.
See More
Obagi Partners with VIO Med Spa to Launch ALOHA Program
- Partnership Announcement: Obagi Medical has partnered with VIO Med Spa to launch the ALOHA Program, which aims to conduct a multi-site evaluation of the Obagi® saypha® MagIQ™ filler, leveraging VIO's innovative injectables and personalized wellness protocols to enhance patient outcomes and experiences.
- Clinical Assessment Focus: The program will standardize data collection to evaluate clinical performance and patient experience, ensuring robust real-world evidence in high-volume aesthetic settings, thereby elevating industry standards and practices.
- Training Initiative: The ALOHA Program will kick off at the upcoming VIO University training, providing two days of expert-led training for the VIO network, aimed at enhancing clinical excellence and patient satisfaction in aesthetic medicine.
- Technological Edge: The Obagi® saypha® MagIQ™, developed using Croma-Pharma GmbH's MACRO Core Technology, delivers high usable HA content and consistent gel distribution, ensuring natural-looking results and predictable injection outcomes, further solidifying Obagi's leadership in the professional skincare market.
See More
Waldencast Faces Securities Fraud Claims, Shares Drop 6.49%
- Investigation Launched: Pomerantz LLP is investigating whether Waldencast plc has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock price volatility.
- Financial Outlook Downgraded: In its Q2 2025 financial report, Waldencast projected net revenue for the full year to be broadly in line with 2024, with an adjusted EBITDA margin in the high single digits, significantly lower than the previously expected mid-teens growth, indicating a notable decline in profitability.
- Substantial Losses: The company reported a net loss of $185.2 million for the first half of 2025, primarily due to impairment charges of $132.1 million and $20 million on its Obagi Medical and Milk Makeup brands, reflecting severe brand value erosion.
- Stock Price Reaction: Following the earnings report, Waldencast's Class A ordinary shares fell by $0.20, or 6.49%, closing at $2.88, indicating a pessimistic market sentiment regarding the company's future prospects.
See More
Waldencast Faces Securities Fraud Claims, Shares Drop 6.49%
- Investigation Launched: Pomerantz LLP is investigating whether Waldencast plc has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock price volatility.
- Financial Outlook Downgraded: In its Q2 2025 earnings report, Waldencast projected full-year net revenue to be in line with 2024, with adjusted EBITDA margins in the high single digits, significantly lower than previous mid-teens guidance, indicating a notable decline in profitability.
- Substantial Loss Reported: The company reported a net loss of $185.2 million for the first half of 2025, primarily due to impairment charges of $132.1 million and $20 million on its Obagi Medical and Milk Makeup brands, highlighting significant challenges to brand value that may affect future investment appeal.
- Stock Price Reaction: Following the earnings report, Waldencast's Class A ordinary shares fell by $0.20, or 6.49%, closing at $2.88, reflecting the market's pessimistic sentiment regarding the company's outlook.
See More
